Business
Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapies designed to remove disease-causing proteins.
Arvinas revenue was flat at $262.6M and the net loss narrowed, but cash burn and equity erosion persisted.
The read at a glance✓ Audited against SEC data
- Business mix — Targeted protein degradationNote
- Revenue — Revenue flat at $262.6MNote
- Profitability — Net loss narrowed to $80.8MNote
- Cash — FCF fell to -$275.7MWatch
- Balance sheet — Equity fell 22.8%Watch
- Insiders — 2 buys / 11 sellsNote
- Accounting — Altman-Z distress; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as ARVINAS, INC. reports it. History and quarterly detail are in the app.
- License$20.0M
Leadership changes
From ARVINAS, INC.'s own filings, the day they're filed.
- Noah Berkowitz · chief medical officer · departureeff. 2026-07-03
- Briggs Morrison · director · appointmenteff. 2026-02-12
- Randy Teel · president · appointmenteff. 2026-02-11
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-06-16
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ARVINAS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.